Skip to main navigation Skip to search Skip to main content

In vitro interactions between farnesol and fluconazole, amphotericin b or micafungin against candida albicans biofilms

  • Aspasia Katragkou
  • , Matthew Mccarthy
  • , Elizabeth L. Alexander
  • , Charalampos Antachopoulos
  • , Joseph Meletiadis
  • , Mary Ann Jabra-rizk
  • , Vidmantas Petraitis
  • , Emmanuel Roilides
  • , Thomas J. Walsh
  • New York Presbyterian Hospital
  • Aristotle University of Thessaloniki
  • Cornell University
  • Attikon University Hospital
  • University of Maryland, Baltimore

Research output: Contribution to journal › Article › peer-review

110 Scopus citations

Abstract

Objectives: Biofilm formation by Candida albicans poses an important therapeutic challenge in human diseases. Typically, conventional antifungal agents encounter difficulty in treating and fully eradicating biofilm-related infections. Novel therapeutic approaches are needed to treat recalcitrant Candida biofilms. Farnesol is a quorum-sensing molecule, which induces apoptosis, inhibits Ras protein pathways and profoundly affects the morphogenesis of C. albicans. We therefore investigated the interactions between farnesol and different classes of antifungal agents. Methods: The combined antifungal effects of triazoles (fluconazole), polyenes (amphotericin B) and echinocandins (micafungin) with farnesol against C. albicans biofilms were assessed in vitro. Antifungal activity was determined by the XTT metabolic assay and confocal microscopy. The nature and the intensity of the interactions were assessed using the Loewe additivity model [fractional inhibitory concentration (FIC) index] and the Bliss independence (BI) model. Results: Significant synergy was found between each of the three antifungal agents and farnesol, while antagonism was not observed for any of the combinations tested. The greatest synergistic effect was found with the farnesol/micafungin combination, for which the BI-based model showed the observed effects as being 39%-52% higher than expected if the drugs had been acting independently. The FIC indices ranged from 0.49 to 0.79, indicating synergism for farnesol/micafungin and farnesol/fluconazole and no interaction for farnesol/amphotericin B. Structural changes in the biofilm correlated well with the efficacies of these combinations. The maximum combined effect was dependent on the farnesol concentration for micafungin and amphotericin B. Conclusions: Farnesol exerts a synergistic or additive interaction with micafungin, fluconazole and amphotericin B against C. albicans biofilms, thus warranting further in vivo study.

Original languageEnglish
Pages (from-to)470-478
Number of pages9
JournalJournal of Antimicrobial Chemotherapy
Volume70
Issue number2
DOIs
StatePublished - 1 Feb 2015

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Antifungals
  • C. albicans
  • Combinations

Fingerprint

Dive into the research topics of 'In vitro interactions between farnesol and fluconazole, amphotericin b or micafungin against candida albicans biofilms'. Together they form a unique fingerprint.

Cite this